Content area
Full Text
Received Feb 22, 2018; Accepted Feb 22, 2018
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Glioblastoma (GBM) is the most aggressive brain tumor in adults. Due to the high degree of heterogeneity, little is known about the molecular events underpinning GBM genesis and the disease is already advanced at clinical presentation, thus complicating the efficacy of therapies.
This special issue provides an update on novel basic and translational advances, which are expected to impact on patient treatment and improve survival.
On the translational front, the review by F. A. Chowdhury et al. focuses on the cytotoxic and antiapoptotic potential of Thymoquinone for GBM treatment by affecting key signaling pathways that promote tumor cell proliferation. Another two reviews by V. Desai and A. Bhushan and M. N. Park et al. highlight the potential of natural compounds in the treatment of this devastating disease both individually and in combination with the standard of care for GBM patients, that is, chemo- and radiotherapy,...